Loading...
Market
How will Rezolute's stock price react within 1 week of FDA decision on RZ358?
2
Resolution / Starting Odds
Stock price increases by over 20% • 25%
Stock price increases by 10-20% • 25%
Stock price changes by less than 10% • 25%
Stock price decreases • 25%
Stock market data (NASDAQ: RZLT)
Story
FDA Lifts Partial Hold on Rezolute's Phase 3 Treatment for Congenital Hyperinsulinism
Sep 9, 2024, 12:00 PM
Rezolute Inc announced on Monday that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on its experimental treatment, RZ358, for congenital hyperinsulinism. This decision allows the inclusion of U.S. participants in the ongoing Phase 3 study. The treatment aims to address low blood sugar levels associated with the condition.
View original story
Similar markets
Increase > 20% • 25%
Increase 10-20% • 25%
Increase < 10% • 25%
Decrease • 25%
Stock increases by more than 10% • 25%
Stock increases by 5-10% • 25%
Stock changes by less than 5% • 25%
Stock decreases • 25%
Increase by 5% or more • 25%
Increase by less than 5% • 25%
Decrease • 25%
No significant change • 25%
Significant Increase (>20%) • 25%
Moderate Increase (10-20%) • 25%
No Significant Change • 25%
Decrease • 25%
Increase by 5% or more • 25%
Increase by less than 5% • 25%
Decrease • 25%
No significant change • 25%
Increase >10% • 25%
Increase <=10% • 25%
Decrease <=10% • 25%
Decrease >10% • 25%
Stock rises by more than 10% • 25%
Stock rises by 0-10% • 25%
Stock falls by 0-10% • 25%
Stock falls by more than 10% • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
No significant change • 25%
Decrease • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increases by more than 10% • 25%
Increases by 0-10% • 25%
Decreases by 0-10% • 25%
Decreases by more than 10% • 25%